Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Accured Expenses Change in Accured Expenses Change in Cash Change in Inventory Change in Inventory Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Dividends Paid - Common Dividends Paid - Common Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Long-Term Debt Repayments Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other Working Capital Changes Other Working Capital Changes Other financing activities Other financing activities Sales of Property, Plant and Equipment Sales of Property, Plant and Equipment Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

ENDRA Life Sciences (NDRA) Asset Writedowns and Impairment (2018 - 2019)

ENDRA Life Sciences has reported Asset Writedowns and Impairment over the past 2 years, most recently at $249256.0 for Q4 2019.

Quarterly Asset Writedowns and Impairment rose 186.69% to $249256.0 in Q4 2019 from the year-ago period, while the trailing twelve-month figure was $249256.0 through Dec 2019, changed N/A year-over-year, with the annual reading at $249256.0 for FY2019, N/A changed from the prior year.
Asset Writedowns and Impairment was $249256.0 for Q4 2019 at ENDRA Life Sciences, up from -$287541.0 in the prior quarter.
Over five years, Asset Writedowns and Impairment peaked at $287541.0 in Q3 2018 and troughed at -$287541.0 in Q4 2018.